Washington Post Reporter Renea Merle: Martin Shkreli would have raised pharmaceutical prices higher than 5,000%

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Former Turing Pharmaceuticals CEO Martin Shkreli arrives to federal court in New York, Monday, June 26, 2017. Even with his federal securities fraud trial set to begin Monday, Shkreli has blatantly defied his attorneys' advice to lay low. (AP Photo/Seth Wenig)

Washington Post DC Reporter Renea Merle gives john the backstory to the Ponzi-like scheme and behaviors of “Pharma Bro” Martin Shkreli. She stands outside of the courthouse and explains why it’s been difficult to compile a jury, out of 200 contenders, on the case of the “most hated man in America.”

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.